COMPANY

HDT Bio Corp.

HDT Bio is a Seattle-based clinical stage biopharmaceutical development company. From company website Source · Oct 13, 2026

Keywords: biopharmaceutical covid-19 influenza leprosy Vaccine Crimean-Congo Hemorrhagic Fever SARS-CoV2 Infection chronic hepatitis b acute flaccid myelitis ovarian cancer sars-cov-2 infection HDT 321 HDT-321 HDT-301

Profile checked Oct 10, 2026

2Trials (company is sponsor)25NIH grants

Funding and NIH signals

NIH award NIH awarded $1.06M (NIH grant 5R01AI180195-03, continuation, notice Jul 24, 2026). NIH RePORTER 5R01AI180195-03 (Jul 24, 2026)
Evidence (1 event)
- Jul 24, 2026 · NIH RePORTER 5R01AI180195-03
  Organization: HDT BIO CORPORATION; City/State: SEATTLE, WA; Project number: 5R01AI180195-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 1063126; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Immunological mechanism of muscle-localizing self-replicating RNA vaccines; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 24, 2026 Grant Government grant — NIH R01: $1.06M (annual award, as published), announced Jul 24, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 1, 2025 Grant Government grant — NIH R01: $1.09M (annual award, as published), announced Aug 1, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 10, 2025 Trial start Phase 1: Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever source ↗
May 14, 2025 Grant Government grant — NIH R33: $981,683 (annual award, as published), announced May 14, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 14, 2025 Grant Government contract: $129,000 (total, as published), announced Apr 14, 2025. Agency: DoD. Source: government award database. source ↗
Jan 24, 2022 Trial start Phase 1: Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever · NCT06799013

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 24, 2026 Government grant — NIH R01: $1.06M (annual award, as published), announced Jul 24, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 1, 2025 Government grant — NIH R01: $1.09M (annual award, as published), announced Aug 1, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
May 14, 2025 Government grant — NIH R33: $981,683 (annual award, as published), announced May 14, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 14, 2025 Government contract: $129,000 (total, as published), announced Apr 14, 2025. Agency: DoD. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06799013	Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever	Phase 1	Recruiting	Jul 10, 2025	2026-12 (estimated)
NCT05132907	Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein	Phase 1	Completed	Jan 24, 2022	Nov 21, 2023 (actual)

NIH awards 25

Annual award amounts. Total $22.7M.

Sep 13, 2024 NIH award 1R01AI180195-01 FY2024: $1,074,519 awarded for that fiscal year; activity R01 (OTHER_NIH); PI KIMURA, TAISHI; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Immunological mechanism of muscle-locali source ↗
May 6, 2024 NIH award 4R33AI161811-04 FY2024: $981,917 awarded for that fiscal year; activity R33 (OTHER_NIH); PI KHANDHAR, AMIT PRAFUL; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Engineering the Immune Response of source ↗
Apr 4, 2024 NIH award 5R61AI169207-03 FY2024: $543,301 awarded for that fiscal year; activity R61 (OTHER_NIH); PI REED, STEVEN GREGORY; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. RNA Vaccine Innovations for TB: Targ source ↗
Aug 30, 2023 NIH award 1R43IP001229-01A1 FY2022: $299,984 awarded for that fiscal year; activity R43 (SBIR); PI BERUBE, BRYAN; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. PA21259, SBIR Phase I, Developing a RIG-I agon source ↗
Apr 28, 2023 NIH award 5R43AI170395-02 FY2023: $192,720 awarded for that fiscal year; activity R43 (SBIR); PI ERASMUS, JESSE HONG-SAE; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development of a single-dose self-ampl source ↗
Apr 14, 2023 NIH award 1R43AI177181-01 FY2023: $275,211 awarded for that fiscal year; activity R43 (SBIR); PI BERUBE, BRYAN; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development of a RIG-I agonist RNA as a cure for source ↗
Mar 23, 2023 NIH award 5R61AI161811-03 FY2023: $940,253 awarded for that fiscal year; activity R61 (OTHER_NIH); PI KHANDHAR, AMIT PRAFUL; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Engineering the Immune Response of source ↗
Mar 21, 2023 NIH award 5R61AI169207-02 FY2023: $538,074 awarded for that fiscal year; activity R61 (OTHER_NIH); PI REED, STEVEN GREGORY; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. RNA Vaccine Innovations for TB: Targ source ↗
May 10, 2022 NIH award 1R43AI170395-01 FY2022: $104,692 awarded for that fiscal year; activity R43 (SBIR); PI ERASMUS, JESSE HONG-SAE; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development of a single-dose self-ampl source ↗
Apr 22, 2022 NIH award 1R61AI169207-01 FY2022: $550,719 awarded for that fiscal year; activity R61 (OTHER_NIH); PI REED, STEVEN GREGORY; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. RNA Vaccine Innovations for TB: Targ source ↗
Mar 15, 2022 NIH award 5R61AI161811-02 FY2022: $1,046,474 awarded for that fiscal year; activity R61 (OTHER_NIH); PI KHANDHAR, AMIT PRAFUL; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Engineering the Immune Response o source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93020C00052-P00002-9999-1 FY2022: $2,717,614 awarded for that fiscal year; activity N01 (OTHER_NIH); PI REED, STEVEN; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Develop source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93022C00017-0-9999-1 FY2022: $1,499,422 awarded for that fiscal year; activity N01 (OTHER_NIH); PI SAR, KANDYMA; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. THERAPEUTICS source ↗
Sep 2, 2021 NIH award 1R43AI165100-01 FY2021: $299,976 awarded for that fiscal year; activity R43 (SBIR); PI ERASMUS, JESSE HONG-SAE; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development of an adaptable RNA vaccin source ↗
Aug 27, 2021 NIH award 1R43CA265564-01 FY2021: $399,285 awarded for that fiscal year; activity R43 (SBIR); PI KHANDHAR, AMIT PRAFUL; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Targeting and Imaging Ovarian Cancer wit source ↗
Apr 26, 2021 NIH award 5R21AI144641-02 FY2021: $265,468 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DUTHIE, MALCOLM S; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Assessing immunogenicity of LepVax: a n source ↗
Apr 9, 2021 NIH award 1R61AI161811-01 FY2021: $927,069 awarded for that fiscal year; activity R61 (OTHER_NIH); PI KHANDHAR, AMIT PRAFUL; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Engineering the Immune Response of source ↗
Mar 16, 2021 NIH award 1R43AI162278-01 FY2021: $223,637 awarded for that fiscal year; activity R43 (SBIR); PI DUTHIE, MALCOLM S; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development of CoroDetecT, a skin test for S source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93020C00052-P00001-9999-1 FY2021: $4,015,904 awarded for that fiscal year; activity N01 (OTHER_NIH); PI REED, STEVEN; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Develop source ↗
May 21, 2020 NIH award 1R21AI144641-01A1 FY2020: $221,223 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DUTHIE, MALCOLM S; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Assessing immunogenicity of LepVax: a source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00052-0-9999-1 FY2020: $4,236,540 awarded for that fiscal year; activity N01 (OTHER_NIH); PI REED, STEVEN; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Development source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00028-0-9999-1 FY2020: $299,959 awarded for that fiscal year; activity N01 (OTHER_NIH); PI CARTER, DARRICK; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Antibody Th source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N93019C00037-0-9999-1 FY2019: $599,629 awarded for that fiscal year; activity N43 (OTHER_NIH); PI ORR, MARK; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. RATIONAL DEVELOPM source ↗
Aug 30, 2018 NIH award 1R43IP001109-01 FY2018: $224,984 awarded for that fiscal year; activity R43 (SBIR); PI ORR, MARK; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Engineering Nanoparticle Alum Adjuvants for Pandemic source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201800019C-0-0-1 FY2018: $221,889 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: HDT BIO CORPORATION, SEATTLE, WA. Diagnostics for Leprosy/M. source ↗